Home/Zevra Therapeutics/Thomas D. Anderson
TD

Thomas D. Anderson

Compensation Committee Chair, Nominating and Corporate Governance Committee

Zevra Therapeutics

Zevra Therapeutics Pipeline

DrugIndicationPhase
MIPLYFFA® (arimoclomol)Niemann-Pick disease type C (NPC)Filed (EU)
OLPRUVA®Urea Cycle Disorders (UCDs)Approved
CeliprololVascular Ehlers-Danlos Syndrome (VEDS) - COL3A1 positivePhase 3
KP1077Idiopathic Hypersomnia / Sleep DisordersPhase 2